Ox1 receptor antagonists
AssigneeNxera Pharma UK Limited
InventorsGiles Albert BROWN, Miles Stuart CONGREVE, John Andrew CHRISTOPHER, Nigel Alan SWAIN, Sarah Joanne BUCKNELL, Anne Mary STEPHENSON, Benjamin Gerald TEHAN, Mark MILLS, Anil PATEL
Life of this patent
Estimating the term…
Abstract
The disclosures herein relate to novel compounds of formula (I); and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
Claims14
A method of treating, ameliorating, controlling, or reducing the risk of neurological or psychiatric disorders, comprising administering an effective amount of the compound of formula (1):
- or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein:
- W is N or CR5;
- X is N or CR6;
- Y is CH2;
- Z is CR7 or N;
- R1 is H or a halogen;
- R2 is a 5 or 6 membered heteroaryl ring containing two or three nitrogen atoms which is optionally substituted with one or more fluorine atoms;
- R3 is H or a halogen;
- R4 is H or a halogen;
- R5 is selected from H;
- halogen;
- C1-C3 alkyl, optionally substituted with OMe or one or
- more halogen groups;
- and C1-C3 alkoxy, optionally substituted with one or more halogen groups;
- R6 is selected from H;
- halogen;
- C1-C3 alkyl, optionally substituted with OMe or one or more halogen groups;
- and C1-C3 alkoxy, optionally substituted with one or more halogen groups;
- and
- R7 is H or a halogen.
Dependencies are inferred from the claim text.